Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion type Assertion NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_head.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion description "[Systematic research at University of Arkansas over the last 10 years, has revealed that the absence of unfavorable cytogenetic abnormalities (deletion of chromosome 13 and hypodiploidy), low beta-2 microglobulin levels prior to transplant, a normal lactate dehydrogenase level at diagnosis and early application of high-dose treatment (< 12 months of preceding standard treatment) define a subgroup of myeloma patients with a high likelihood of long (> 5 years) event-free survival; a sizable minority of these patients may be considered cured.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_provenance.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion evidence source_evidence_literature NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_provenance.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion SIO_000772 12802910 NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_provenance.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion wasDerivedFrom befree-20140225 NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_provenance.
- NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_assertion wasGeneratedBy ECO_0000203 NP540172.RAz25ZigW8Q8EZXBoIpUoc2-4oRHU7Tn9AtPWWxNTK7_Y130_provenance.